Form 4: ImmunityBio Director Receives Stock Option Grant

Director Bruce Wendel was granted 65,600 stock options in ImmunityBio, Inc. under the company's 2025 Equity Incentive Plan.

Summary

• Director Bruce Wendel received a grant of 65,600 stock options on June 9, 2026.
• The options have an exercise price of $7.25 per share.
• The options are set to expire on June 9, 2036.
• The award is subject to a vesting schedule tied to continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director remaining a service provider to the company.

Future Outlook

The options vest in full on the earlier of June 9, 2027, or the date immediately preceding the next annual meeting of stockholders, provided the director remains a service provider.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure board members are incentivized to drive long-term company performance in the biotechnology sector.

Comparison to Industry Standards

• The use of equity-based compensation for board members is consistent with standard practices for mid-cap biotechnology firms.
• The 10-year expiration term is standard for executive and director stock option plans.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 9, 2027, or the day before the next annual meeting.

Key Dates

Keywords

ImmunityBio, IBRX, Form 4, Stock Options, Director Compensation, Insider Transaction